A Phase III Confirmatory Study of K-237
NCT05056883
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1030
Enrollment
INDUSTRY
Sponsor class
Conditions
Covid19
Interventions
DRUG:
K-237 0.3-0.4mg/kg (once daily)
DRUG:
Placebo 0.3-0.4mg/kg (once daily)
Sponsor
Kowa Company, Ltd.